- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01672463
Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients (OKN-007)
March 28, 2023 updated by: Oblato, Inc.
Phase 1b Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients
This is an open label Phase 1b clinical trial of IV administration of OKN-007 in a pilot cohort of human recurrent malignant glioma patients.
All patients will have been previously treated with the standard-of-care treatment which includes surgical resection, radiation and chemotherapy, and in some cases treatment for recurrent disease with investigational agents or bevacizumab (Avastin).
Patients with unequivocal recurrence (first or greater) established by MRI with and without contrast (e.g., Gd-DTPA (Gadolinium-diethylene triamine pentacetic acid) and meeting inclusion and exclusion criteria, will be eligible for OKN-007 treatment on this protocol.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
31
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Confirmed histopathology of WHO grade III glioma or WHO grade IV GBM at primary diagnosis
- Unequivocal radiographic evidence of tumor progression by MRI within 14 days prior to registration
- Prior radiotherapy
- Prior Temozolomide treatment
- Last cytotoxic chemotherapy 28 or more days or biologic therapy treatment 14 or more days before study start (greater than or equal to 42 days if nitrosourea was administered)
- Karnofsky performance status greater than or equal to 60%
- Full recovery (< grade 1) from the toxic effects of any earlier intervention and a minimum of 28 days from the administration of any investigational agent
Adequate renal, liver and bone marrow function:
- Leukocytes >3,000/mcL
- Absolute neutrophil count >1,500/mcL
- Platelets >100,000/mcL
- Total bilirubin within normal limits
- AST / ALT (SGPT) <2.5 x ULN
- Creatinine within normal limits
- Patients must be >_18 years of age
Exclusion Criteria:
- Second primary malignancy (except adequately treated basal cell carcinoma of the skin). Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
- Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
- Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
- Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
- Patients with PT/PTT above the upper limit of normal
- Screening ECG abnormality documented by the investigator as medically significant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: All patients
All participants enrolled in this study
|
Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter. Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Adverse events per patient
Time Frame: 24 months
|
The primary objective is to determine MTD, tolerance, and safety of OKN-007 in patients with recurrent GBM and anaplastic glioma.
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK level in participants
Time Frame: 24 months
|
To determine drug levels of OKN-007 in blood.
|
24 months
|
6 month progression-free survival
Time Frame: 24 months
|
To determine radiographic response rate and 6 month Progression-Free Survival (PFS) of patients treated with OKN-007.
PFS is defined as the time from first drug treatment until objective tumor progression or death.
|
24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: James Battiste, MD, PhD, • Oklahoma University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2012
Primary Completion (Actual)
January 31, 2023
Study Completion (Anticipated)
October 1, 2023
Study Registration Dates
First Submitted
August 21, 2012
First Submitted That Met QC Criteria
August 23, 2012
First Posted (Estimate)
August 24, 2012
Study Record Updates
Last Update Posted (Actual)
March 29, 2023
Last Update Submitted That Met QC Criteria
March 28, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HCI57337
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Malignant Glioma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Food and Drug Administration (FDA)Active, not recruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Refractory Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II Glioma | Refractory Glioblastoma | Refractory WHO Grade II Glioma | Refractory WHO Grade III GliomaUnited States
-
Sabine Mueller, MD, PhDPacific Pediatric Neuro-Oncology ConsortiumRecruitingGlioblastoma | Malignant Glioma | Recurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent Grade III Glioma | Grade III GliomaUnited States, Australia, Israel, Switzerland
-
Jonsson Comprehensive Cancer CenterUnited States Department of DefenseRecruitingGlioma | Malignant Glioma | Recurrent Malignant Glioma | Recurrent GliomaUnited States
-
INSYS Therapeutics IncPediatric Brain Tumor Consortium (PBTC), St. Jude Children's Research HospitalWithdrawnRecurrent Malignant GliomaUnited States
-
Memorial Sloan Kettering Cancer CenterM.D. Anderson Cancer Center; University of California, Los Angeles; University... and other collaboratorsActive, not recruitingGlioma | Recurrent Malignant GliomaUnited States
-
Medical University InnsbruckRoche, AustriaUnknownRecurrent Malignant GliomaAustria
-
National Cancer Institute (NCI)Active, not recruitingGlioblastoma | WHO Grade 3 Glioma | Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Recurrent Glioma | Recurrent Cholangiocarcinoma | WHO Grade 2 GliomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Glioblastoma | Recurrent Malignant Glioma | Recurrent WHO Grade III Glioma | Recurrent WHO Grade II GliomaUnited States
-
Oblato, Inc.Active, not recruitingRecurrent Malignant Glioma | Brain GlioblastomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Malignant Glioma | Recurrent Medulloblastoma | Refractory Malignant Glioma | Refractory Medulloblastoma | Recurrent Diffuse Intrinsic Pontine Glioma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central Nervous System Neoplasm | Refractory Diffuse Intrinsic Pontine...United States, Canada
Clinical Trials on OKN-007
-
Oblato, Inc.RecruitingAstrocytoma | Glioblastoma Multiforme | Oligodendroglioma | High-grade GliomaUnited States
-
Oblato, Inc.AvailableDiffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-MutantUnited States
-
Oblato, Inc.WithdrawnGlioblastoma | Astrocytoma | Oligodendroglioma
-
University of OklahomaActive, not recruitingOKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed GlioblastomaGlioblastomaUnited States
-
Oblato, Inc.Active, not recruitingRecurrent Malignant Glioma | Brain GlioblastomaUnited States
-
Apollo Therapeutics LtdTerminatedAdult Onset Still's DiseaseUnited States, Belgium, Poland, Ukraine
-
Dr. August Wolff GmbH & Co. KG ArzneimittelParexelCompletedDermatitis, AtopicGermany
-
Qilu Pharmaceutical Co., Ltd.Unknown
-
Nanjing Leads Biolabs Co.,LtdRecruitingAdvanced Solid TumorChina
-
Suzhou Yabao Pharmaceutical R&D Co., Ltd.Suspended